Insight Molecular Diagnostics Has $11.8 Million In Cash, Targets $8 Million In Quarterly Outflow
Lower submission costs helped curb spending, but FDA authorization remains the gate to meaningful clinical-test kit sales.
Insight Molecular Diagnostics, which develops tests to monitor transplanted organs for rejection, reported $11.8 million in third-quarter-end cash, including restricted funds, in results furnished with Monday's SEC filing. Management targets approximately $8 million in fourth-quarter cash outflow after capital spending as it prepares more evidence for its paused kidney-test FDA review.
Spending Eases, Cash Remains Central
Third-quarter cash outflow after capital spending was approximately $7.3 million, below management's $8 million expectation. Operations used $6.4 million, and capital spending totaled about $841,000.
The cash balance compared with $18.7 million at second-quarter end and $20.2 million a year earlier. Cash and cash equivalents alone were $11 million; the headline balance includes restricted money.
Adjusted operating expenses fell 15% from the second quarter to $6.7 million, unchanged from a year earlier. Management attributed the sequential reduction to lower spending connected with the GraftAssureDx submission, including consulting, software development and clinical-study services.
Research and development spending fell to $3.8 million from $4.5 million in the second quarter. Sales and marketing spending declined to $1.6 million from $1.9 million, partly because a $110,000 research grant and conference costs belonged to the second quarter. General and administrative spending was $2.8 million, versus $2.9 million the prior quarter.
Clinical Evidence Holds Up The Kit
GraftAssureDx would let transplant centers run kidney-rejection testing in their own laboratories. The FDA requested more information in late July, principally about the clinical validation study's design and analysis. Its preliminary assessment was that the evidence submitted did not yet support the proposed use.
Insight submitted the kit in March 2026 and met with the agency in late September to discuss its response. Management expects an independent study of test accuracy and consistency, plus biopsy-slide reviews by two expert pathologists, to finish before year-end.
The company expects to deliver its complete response before January 21, 2027. Management estimates approximately half of the FDA's targeted 150-day review period remains and expects the paused clock to restart when the response is submitted.
Meaningful kit revenue depends on marketing authorization, management said. Today, GraftAssureCore testing runs at the company's Franklin, Tennessee laboratory and receives Medicare reimbursement; GraftAssureIQ kits are sold for research use. UCLA Medical Center has begun enrolling patients in the GALACTIC registry study, which management expects to bring more GraftAssureCore testing revenue as enrollment and participating sites expand.
The company announced Donnie Purto's appointment as senior vice president of sales on October 14, 2026, to prepare commercialization. Management plans to expand commercial staffing as revenue and adoption justify it.
The Loss Improvement Was Mostly Non-Cash
The third-quarter net loss narrowed to $3.6 million, or $0.10 per share, from $10.9 million, or $0.34 per share, a year earlier. A $4.1 million non-cash gain from revaluing contingent payment obligations largely accounted for the improvement.
The adjusted loss showed a smaller change: $6.8 million, or $0.19 per share, versus $7 million, or $0.22 per share. Weighted-average shares rose to 36.9 million from 32 million, including 4.1 million shares underlying unexercised pre-funded warrants.
Revenue rose to $559,000 from approximately $260,000 a year earlier, mostly from laboratory services. Research-use kit sales contributed $21,000, versus zero. Gross profit reached $420,000 from $139,000, with gross margin increasing to 75.1% from 53.5%.
The next regulatory step is the company's planned response before January 21, 2027; FDA marketing authorization remains pending.